Skip to content
Screener
DaVita logo

DaVita

DVA

DaVita is a leading healthcare provider specializing in comprehensive kidney care and dialysis services for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD).

Market cap
$11.67B+33.7%
Revenue$14.2B+6.4%
Net income$920.1M+19.2%
Free cash flow$1.3B+0.1%
EPS (diluted)$13.51+39.4%
Trailing twelve months · change vs. prior year

Earnings

Next report

Feb 1, 2027 (in 2 months)
Revenue estimate$3.6B
EPS estimate$4.14

Financials

Q3 2026

Income statement

See full
Revenue$3.6B+4.6%
Operating income$499.3M-1.3%
Net income$222.9M+48.3%
EPS (diluted)$3.40+66.7%

Balance sheet

See full
Cash & equivalents$495.6M-37.7%
Total debt$13.4B+4.3%
Total equity-$591.1M-3.4%
Total assets$17.8B+1.5%

Cash flow

See full
Operating cash flow$518.8M-38.3%
CapEx$159.5M-4.0%
Free cash flow$359.3M-46.8%

Valuation & ratios

Valuation

See full
Market cap$11.67B+33.7%
Enterprise value$24.57B+19.7%
P/E12.7×+1.7×
P/S0.8×+0.2×

Profitability

See full
Operating margin15%-0.4pp
Net margin6.5%+0.7pp
FCF margin9.1%-0.6pp

Returns & leverage

See full
Current ratio1.4×0.0×

Segments

By segment

See full
Other - Ancillary Services$252.8M+6.4%

Competitors

Profile

DaVita is a leading healthcare provider specializing in comprehensive kidney care and dialysis services for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The company operates a global network of outpatient centers and provides integrated care management, laboratory services, and hospital inpatient treatments. Its core value proposition focuses on improving clinical outcomes and patient quality of life through a patient-centric care model and value-based care arrangements.

Competitive position

DaVita is a leading provider of dialysis services in the U.S. and a global leader in clinical quality, maintaining a significant market share alongside major competitors like Fresenius.

GeographiesUnited States, Brazil, Colombia, Malaysia, Poland, Germany, United Kingdom, Saudi Arabia, China
Customer segmentsPatients, Government agencies, Commercial insurers, Hospitals
Business modelFee-for-service, Value-based care, Risk-based integrated care, Management services
SuppliersMedical equipment manufacturers, Pharmaceutical suppliers, Nephrologists and physician groups, Specialized clinical labor
CustomersMedicare and Medicaid programs, Commercial health insurance plans, Acute care hospitals, ESKD and CKD patients
Listed1995
Employees70.0K
CEOJavier J. Rodriguez
Websitedavita.com
FilingsSEC EDGAR

FAQ

What is DaVita's market cap?
DaVita (DVA) has a market capitalization of $11.7B and trades on NYSE.
What is DaVita's revenue and profitability?
DaVita generated $14.2B in trailing twelve-month revenue with net income of $920.1M, representing a net margin of 6.5%, with free cash flow of $1.3B. The latest reported period is Q3 2026.
Who are DaVita's competitors?
DaVita's key competitors include Outset Medical, Inc. Common Stock, UnitedHealth Group, Baxter International Inc., and others. These companies compete in similar markets and product categories.
Who does DaVita partner with?
DaVita's notable partners include United States Department of Veterans Affairs, Centers for Medicare & Medicaid Services.
What subsidiaries does DaVita have?
DaVita's subsidiaries include MedSleuth, DaVita Clinical Research, DaVita Venture Group.
Where is DaVita headquartered?
DaVita is headquartered in United States of America and employs approximately 70,000 people. It has been publicly traded since 1995.